tcm55 Financing the DMT Trial is from selling 37% of AGNNeuro shares. So Yes, I believe that is a fair deal for AGN shareholders.
M$ It does not address the question(s) I asked. Which is regarding advertising for the DMT program that is now in the hands of a SUBSIDIARY company of Algernon Pharmaceuticals Inc. As I've said, AGN/PF shareholders are paying 100% of the cost of advertising for Algernon Neuroscience with a share structure independent of the shares you may own. Diluting one group of shareholders to prop up another group of shareholders. That's the same type of dilution scheme Kulwant Malhi orchestrated by flipping millions of AGN shares for Growmax Resources shareholders. All while Moreau (CEO) and Williams (CSO) worked for Malhi at First Responder Technologies, now a bankrupt company. Let me guess, ^that's just fine and dandy as well? However, it is Algernon Pharmaceuticals after-all. There's ample historical reasons the stock price remains in the sewer beneath ground level no matter what comes out of the CEO’s mouth next.
tcm55 COVID was scammed by Phiser/Fousi and even MDNA was pushed aside. All repurposed drugs from several companies were forced to do Trials while Phiser was given a pass and subsidized Trials/research. So inaccurate question IMO., but there are many articles on these subjects.
M$ Sir, that honestly sounds like a theory that I see no point in getting muddled in.
tcm55 Ifenprodil did not fail it's CT and there were significant benefits proven including IL-6 for COVID patients and CC reduction / slowing rate of IPF in that 2nd Phase 2 CT for Ifenprodil. i.e. a Phase 2b CT for CC this summer/asap... I would talk about Cancer But Cancer use for Ifenprodil is another repurposed direction still being applied for ODD/IND status at the FDA and a current CT is not being planned. Maybe later as with the CKD drug. So Yes. ...(I have discussed Cancer in private, confidentially, but I dislike malfeasant sour grapes, so that's over) ....!!
M$ The bottomline is the COVID-19 study DID NOT advance to Phase III because of weak data. Hence, the study was a failure. If you don’t believe me ask expert analyst Andre Uddin (Algernon Pharmaceuticals lone analyst) who covers the stock.
“Commenting on the results, Uddin wrote, “The lack of a dose-dependent effect in a clinical trial normally suggests poor efficacy of a compound. AGN disclosed 40 mg ifenprodil did not show any effects in this study while the 20 mg dose demonstrated some trends. Based on the lack of dose response, we unfortunately would not expect this indication to be advanced.”
M$ Better yet, have Algernon Pharmaceuticals release the written recommendations given to them by the FDA. My best guess is a move to Phase III would have been catastrophically stupid and futile.
tcm55 Accusing the AGN CEO of being a drunk is a TOS violation, IMHFO…
M$ It’s a typo. Drunk should have read as drum…beating drum…not beating drunk. Get it now?
tcm55 If you dont like the company;s format for repurposed drugs then sell the rest of any shares you may still have and move on. I plan to buy more.
M$ I’ve heard it all before.
tcm55 Taking comments out of context, ie Shell, is unfair IMO
M$ You have exactly what was posted by shell in BLACK and WHITE. Ask him or anyone else if they think I somehow misinterpreted the facts.
IMO, there remains ZERO legitimate rebuttals to ANY of the concerns I’ve raised regarding Algernon Pharmaceuticals Inc.
News 
Market Data 
Discover 
